Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills
Patent
1997-04-24
1999-03-30
Page, Thurman K.
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Tablets, lozenges, or pills
424464, 424474, 424487, 424497, 427215, 427216, 427213, 42721336, 427212, 514960, 514962, 514963, 514964, A61K 922
Patent
active
058885455
DESCRIPTION:
BRIEF SUMMARY
This application is based on German Patent Application DE 4423078.8 filed Jul. 1, 1994 and PCT/DE95/00805, filed Jun. 22, 1995, the contents of which are incorporated hereinto by reference.
BACKGROUND OF THE INVENTION
The invention is relative to an orally applicable carbamazepine medicament with retarded active substance release. Carbamazepine, a 5 H-dibenz(b,f)azepine-5-carboxamide, is used in particular as an antiepileptic. Commercial forms of administration are tablets with 200 mg active substance, delayed-action tablets with 200 to 600 mg active substance and syrups.
It is known that carbamazepine very rapidly forms a dihydrate upon contact with water. This dihydrate is present in a crystalline form as needles which can grow up to a particle size of 500 .mu.m. This has a negative effect on the further processing, especially when developing retarding coatings. The known methods of production therefore do not use aqueous media and prefer to use organic solvents.
The retarding of an active substance can take place in various ways. DE patent 23 77 520 describes a formulation for carbamazepine in which the active substance is mixed with customary inactive tableting ingredients and pressed to a core or filled into capsules. The core or the capsule is coated with a methacrylic acid-methacrylic acid methylester mixture dissolved in isopropanol which mixture contains acetyltributylcitrate as softener. In this manner the forming of dihydrate by carbamazepine is prevented by the use of an organic solvent.
DE patents 38 68 077 and 37 25 824 claim a carbamazepine inactive ingredient composition containing a protective colloid which inhibits the crystalline growth of carbamazepine in the presence of water. The carbamazepine-containing core is coated in them with an organic solvent of cellulose acetate. A passage in the form of a perforation is placed in the film in a suitable manner.
The methods of producing these formulations have the disadvantage that the work must be carried out with organic solvents, which impacts the environment and signifies great effort and expense.
Furthermore, these medicaments produced as described above (tablets and capsules) are not divisible, since the casing is damaged in a division and the retarding action is lost therewith. Thus, the dosing possibilities are limited.
In addition, preparations (tablets) are known which do not lose their retarding action in a division or a disintegration into individual particles in liquids outside of or within the gastrointestinal tract. Pharm. Ind. 55, No. 10 (1993) pp. 940-947 describes compact oral preparations in which individual particles are coated with aqueous dispersions of copolymers of methacrylic acid and methylmethacrylic acid esters and pressed to tablets. The addition of 25-50% inactive ingredients brings about a more rapid decomposition of the tablets. The addition of a softener makes it possible to considerably increase the elongation at break of the coating and assures the mechanical stability. The coating of paracetamol-, potassium chloride- and acetylsalicylic acid active substance crystals, theophylline granulate and indomedacine and theophylline pellets are cited in this connection.
The present invention has the problem of making available a carbamazepine medicament in which, in spite of the use of water as solvent or dispersing agent, the crystal growth associated with the formation of dihydrate by the carbamazepine is prevented and the release of the carbamazepine is sufficiently retarded.
SUMMARY OF THE INVENTION
The invention solves the problem in that film formers are applied in combination with a softener as aqueous solution and/or dispersion onto carbamazepine. The coated carbamazepine can optionally be mixed with further inactive ingredients and pressed to tablets or filled into capsules.
DETAILED DESCRIPTION OF THE INVENTION
Polymethacrylate dispersions are used as film formers for the retarding of carbamazepine. The following are preferred: (Eudragit.RTM. NE 30 D), polytrimethylammonioethylmethacrylate chloride
REFERENCES:
patent: 4572833 (1986-02-01), Pedersen et al.
Embase Abstract No. 93329228 & Pharm.Ind. 1993, Band 55, No. 10, S.940-947.
Drug Development and Industrial Pharmacy, vol. 17, No. 13, 1991, pp. 1753-1764, P. Guinchedl et al:, "Carbarnazepine modified release dosage form".
Landgraf Karl-Friedrich
Reiss Sabine
Schubert Eberhard
Arzneimittelwerk Dresden GmbH
Channavajjala Lakshmi
Page Thurman K.
LandOfFree
Carbamazepine medicament with retarded active substance release does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Carbamazepine medicament with retarded active substance release, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carbamazepine medicament with retarded active substance release will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1212089